T cells expressing CD19-specific chimeric antigen receptors (CAR.CD19) can produce high rates of complete remission among patients with refractory B-cell malignancies. However, these studies have also revealed (i) difficulties in preparing sufficient numbers of CAR-T cells from the majority of pediatric patients with non-Hodgkin lymphoma (NHL), and (ii) a growing fraction of NHL patients with delayed relapse due to inadequate persistence of CAR-T cells or loss of CD19 from tumor cells. The long-term goal of Project 4 is to develop a safe and effective immunotherapy for NHL using both the natural and engineered properties of CD1d-restricted Va24-invariant natural killer T (NKT) cells. NKTs are attractive candidates for immunotherapy. They have antilymphoma activity via direct cytotoxicity against CD1d+ lymphoblasts or by activation of other immune effectors, such as NK cells; further, allogeneic NKTs do not produce graft- versus-host disease (GvHD) and can be prepared as ?off-the-shelf? products. We hypothesize that allogeneic NKTs engineered to express CAR.CD19 will show curative potential against NHL without the introduction of GvHD, a concept supported by our preliminary findings: NKTs transduced with CAR.CD19 directly kill CD19+ B lymphoblasts, can be expanded to clinical scale, and exert potent antitumor activity in xenogeneic lymphoma models. We have also shown that the CD62L+ subset of NKTs is essential for CAR.CD19-Tcell persistence and antitumor activity in vivo, and have devised means to preserve this subset of cells during CAR.CD19-NKT expansion. The following three specific aims will test our hypothesis: 1) Generate allogeneic CAR.CD19-NKTs with preserved CD62L expression and maximal antilymphoma potential, using the costimulatory aAPCs (artificial antigen-presenting cells, previously generated during the current funding period). 2) Determine the safety and antitumor activity of third-party CAR.CD19-NKTs in adult and pediatric patients with relapsed/refractory B-cell NHL. 3) Correlate the persistence, phenotype and function of CAR.CD19-NKTs with clinical responses. This study will the first in man to test the feasibility and therapeutic potential of immunotherapy with CAR-redirected NKTs. Our emphasis on CAR.CD19, with its favorable track record when expressed by T cells in NHL patients, will allow us to assess NKTs as a novel platform for NHL immunotherapy and perhaps other types of cancer as well.

Public Health Relevance

Even as reports of successful CAR-directed T-cell immunotherapy for B-cell cancers continue to appear, it is clear that many patients will not benefit in the long term from this treatment. Thus, alternative sources of immune cells that may offer unique advantages over traditional T cells are urgently needed. This project will explore the clinical utility in lymphoma patients of ?natural killer? T (NKT) cells expressing CAR molecules directed to the CD19 target antigen on tumor cells. NKT cells are promising candidates for immunotherapy because they do not induce graft-vs.-host disease and have multiple routes by which they can kill lymphoma cells.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA126752-13
Application #
9759787
Study Section
Special Emphasis Panel (ZCA1)
Project Start
Project End
Budget Start
2019-09-01
Budget End
2020-08-31
Support Year
13
Fiscal Year
2019
Total Cost
Indirect Cost
Name
Baylor College of Medicine
Department
Type
DUNS #
051113330
City
Houston
State
TX
Country
United States
Zip Code
77030
Mamonkin, Maksim; Mukherjee, Malini; Srinivasan, Madhuwanti et al. (2018) Reversible Transgene Expression Reduces Fratricide and Permits 4-1BB Costimulation of CAR T Cells Directed to T-cell Malignancies. Cancer Immunol Res 6:47-58
Velasquez, Mireya Paulina; Bonifant, Challice L; Gottschalk, Stephen (2018) Redirecting T cells to hematological malignancies with bispecific antibodies. Blood 131:30-38
Kalra, Mamta; Gerdemann, Ulrike; Luu, Jessica D et al. (2018) Epstein-Barr Virus (EBV)-derived BARF1 encodes CD4- and CD8-restricted epitopes as targets for T-cell immunotherapy. Cytotherapy :
Ngai, Ho; Tian, Gengwen; Courtney, Amy N et al. (2018) IL-21 Selectively Protects CD62L+ NKT Cells and Enhances Their Effector Functions for Adoptive Immunotherapy. J Immunol 201:2141-2153
Morita, Daisuke; Nishio, Nobuhiro; Saito, Shoji et al. (2018) Enhanced Expression of Anti-CD19 Chimeric Antigen Receptor in piggyBac Transposon-Engineered T Cells. Mol Ther Methods Clin Dev 8:131-140
Bollard, Catherine M; Tripic, Tamara; Cruz, Conrad Russell et al. (2018) Tumor-Specific T-Cells Engineered to Overcome Tumor Immune Evasion Induce Clinical Responses in Patients With Relapsed Hodgkin Lymphoma. J Clin Oncol 36:1128-1139
Lyon, Deborah; Lapteva, Natasha; Gee, Adrian P (2018) Absence of Replication-Competent Retrovirus in Vectors, T Cell Products, and Patient Follow-Up Samples. Mol Ther 26:6-7
Su, Jianzhong; Huang, Yung-Hsin; Cui, Xiaodong et al. (2018) Homeobox oncogene activation by pan-cancer DNA hypermethylation. Genome Biol 19:108
Nabekura, Tsukasa; Chen, Zhiying; Schroeder, Casey et al. (2018) Crk Adaptor Proteins Regulate NK Cell Expansion and Differentiation during Mouse Cytomegalovirus Infection. J Immunol 200:3420-3428
Shum, Thomas; Kruse, Robert L; Rooney, Cliona M (2018) Strategies for enhancing adoptive T-cell immunotherapy against solid tumors using engineered cytokine signaling and other modalities. Expert Opin Biol Ther 18:653-664

Showing the most recent 10 out of 270 publications